WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
Saved in:
| Main Authors: | Jonathan Barratt, Biruh Workeneh, Sung Gyun Kim, Eun Young Lee, Chun Lam, Bess Sorensen, Yuanbo Song, Zeeshan Khawaja, Laura Kooienga |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924033795 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01) -
IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01) -
2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01) -
Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01) -
Corrigendum to “Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review”
Published: (2025-07-01)